Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
TBC leniolisib Activated phosphoinositide 3 kinase delta syndrome Pending
TBC pegcetacoplan Geographic atrophy secondary to age-related macular degeneration Pending
TBC cabotegravir HIV-1 infection, pre-exposure prophylaxis Active
TBC filgrastim Prevention or treatment of neutropenia in various indications Cancelled
TBC filgrastim Cancelled
TBC exagamglogene autotemcel Transfusion-dependent β-thalassemia Pending
TBC exagamglogene autotemcel Sickle cell disease (SCD) Pending
TBC ravulizumab Paroxysmal nocturnal hemoglobinuria. Withdrawn
TBC halobetasol propionate and tazarotene Psoriasis, moderate to severe plaque Withdrawn
TBC abaloparatide Osteoporosis, postmenopausal women Withdrawn